In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

Futures are trading higher as we get ready to start the first full week of trading for the third quarter, as traders and ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic ...

A Congressional investigation is looking into whether drug trials in China that involved U.S. companies possibly took place ...

Bepirovirsen reduced posttreatment markers of hepatitis B infection at 72 weeks, with 20% of recipients achieving functional ...

Noel Anderson, CSO at American Red Cross, Sirsij Peshin, CPO at Pfizer & Lauren Riley, CSO at United Airlines, on how ...

The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.